NRx Pharmaceuticals (NRXP)
(Delayed Data from NSDQ)
$3.54 USD
+0.40 (12.74%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $3.75 +0.21 (5.93%) 7:58 PM ET
3-Hold of 5 3
F Value A Growth F Momentum D VGM
Income Statements
Fiscal Year end for NRx Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 28 | 44 | 116 | 1 | 1 |
Income After Depreciation & Amortization | -28 | -44 | -116 | -1 | -1 |
Non-Operating Income | -2 | 5 | 23 | 0 | 1 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -30 | -40 | -93 | 0 | 0 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -30 | -40 | -93 | 0 | 0 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -30 | -40 | -93 | 0 | 0 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -28 | -44 | -116 | -1 | -1 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -28 | -44 | -116 | -1 | -1 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 7.58 | 6.58 | 4.69 | NA | NA |
Diluted EPS Before Non-Recurring Items | -3.70 | -6.80 | -74.10 | NA | NA |
Diluted Net EPS (GAAP) | -4.00 | -6.00 | -74.40 | -1.60 | -1.10 |
Fiscal Year end for NRx Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 4.40 | 5.80 | 8.19 | 9.44 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -4.40 | -5.80 | -8.19 | -9.44 |
Non-Operating Income | NA | 0.15 | -0.21 | -0.53 | -1.60 |
Interest Expense | NA | 0.08 | 0.04 | 0.00 | 0.00 |
Pretax Income | NA | -4.33 | -6.06 | -8.72 | -11.04 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -4.33 | -6.06 | -8.72 | -11.04 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -4.33 | -6.06 | -8.72 | -11.04 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 7.58 | 8.20 | 7.32 | 6.75 |
Diluted EPS Before Non-Recurring Items | NA | -0.50 | -0.70 | -1.20 | -1.30 |
Diluted Net EPS (GAAP) | NA | -0.50 | -0.70 | -1.20 | -1.60 |